FDA advisors back Moderna's COVID-19 vaccine for older kids - Los Angeles Times
Advertisement

FDA advisors back Moderna’s COVID-19 vaccine for older kids

A vial of the Moderna COVID-19 vaccine on a counter
A vial of the Moderna COVID-19 vaccine on a counter at a pharmacy in Portland, Ore. A government advisory panel has endorsed the company’s vaccine for school-age children and teens.
(Jenny Kane / Associated Press)
Share via

A government advisory panel Tuesday endorsed a second brand of COVID-19 vaccine for school-age children and teenagers.

The Food and Drug Administration’s outside experts voted unanimously that Moderna’s vaccine is safe and effective enough to give kids ages 6 to 17. If the FDA agrees, it would become the second option for those children, joining Pfizer’s vaccine.

The same FDA expert panel will meet Wednesday to consider tot-sized shots from Moderna and Pfizer for the littlest kids, those under 5.

Advertisement

Moderna’s COVID-19 vaccine has long been available for adults in the U.S. and elsewhere and more than three dozen countries offer it to children, too. If the FDA authorizes Moderna’s vaccine for teens and younger children, the next step is for the Centers for Disease Control and Prevention to decide whether to recommend the shots.

The Massachusetts company is seeking clearance for two doses, and plans to later offer a booster. Tuesday’s vote was only for two doses — full-strength for youngsters 12-17 and half-sized doses for those 6-11.

“The data do support that the benefits outweigh the risks for both of these doses, in both of these age groups,” said the CDC’s Dr. Melinda Wharton, a member of the advisory panel.

Newfangled COVID-19 vaccines have left many people yearning for an old-school alternative. The one from Novavax could fit that bill.

May 16, 2022

The FDA held up Moderna’s teen vaccine for months while it investigated a rare side effect, heart inflammation. That’s mostly a risk for teen boys and young men, and also can occur with the Pfizer vaccine. Moderna got extra scrutiny because its shots are a far higher dose.

Advertisement

In their review, FDA scientists said there were no confirmed cases of the heart inflammation in Moderna’s youth studies. But experts say the studies may have had too few participants for a rare side effect like that to appear.

“That clearly needs to be watched closely going forward as we expand the use of the vaccine,” said Dr. Mark Sawyer, a panel member from UC San Diego’s medical school.

As for other side effects, FDA officials said nothing worrisome was reported — mainly sore arms, headache and fatigue.

Advertisement

The FDA analysis concluded that two doses of Moderna are effective in preventing symptomatic COVID-19 illness in teens and younger kids, with the levels of virus-fighting antibodies comparable to those developed in young adults.

Vaccine effectiveness was estimated at 93% for the teens, and 77% for the younger children, according to the FDA analysis. However, the research was done when earlier versions of the coronavirus were causing most U.S. infections, and it’s not clear how well they work against the more contagious Omicron variant and its even more transmissible subvariants.

The analysis is also based on a limited number of COVID-19 cases, making the estimates a bit rough.

A federal health review says Pfizer’s COVID-19 vaccine appears effective in children under 5, the only group not currently eligible for inoculation.

June 13, 2022

A booster shot was added to the studies, and data is expected in about the next month, Moderna officials said. Booster shots are now recommended for children vaccinated with Pfizer’s shots, as well as for all adults.

How much demand there will be for Moderna’s shots isn’t clear. Teens became eligible a year ago for Pfizer’s vaccine, which uses the same technology, and only 60% have gotten two doses. Shots for younger kids started in November; about 29% have been fully vaccinated, according to the CDC.

If the FDA authorizes Moderna shots for teens and schoolchildren, the CDC is not expected to review the vaccine until later this month, according to an agency spokesperson.

Advertisement